· 第三十二條 所有研究均應(yīng)當(dāng)有總結(jié)報(bào)告。總結(jié)報(bào)告應(yīng)當(dāng)經(jīng)質(zhì)量保證部門審查,最終由專題負(fù)責(zé)人簽字批準(zhǔn),批準(zhǔn)日期作為研究完成的日期。研究被取消或者終止時(shí),專題負(fù)責(zé)人應(yīng)當(dāng)撰寫簡要試驗(yàn)報(bào)告。 |
· Section II 9.1.1. A final report should be prepared for each study. In the case of short- term studies, a standardised final report accompanied by a study specific extension may be prepared. 9.1.2. Reports of Principal Investigators or scientists involved in the study should be signed and dated by them. 9.1.3. The final report should be signed and dated by the Study Director to indicate acceptance of responsibility for the validity of the data. |
· 58.185 (a) A final report shall be prepared for each nonclinical laboratory study. (b) The final report shall be signed and dated by the study director. |
· 要求一致,每一個(gè)研究都要有一份總結(jié)報(bào)告,且由專題負(fù)責(zé)人簽名簽日期。 · CFDA中提出項(xiàng)目終止,對報(bào)告的要求;OECD中描述了對多場所研究PI report的要求,且描述了SD簽署報(bào)告的含義。 |
· 第三十三條 總結(jié)報(bào)告主要內(nèi)容應(yīng)當(dāng)包括: |
· Section II 9.2 Content of the Final Report The final report should include, but not be limited to, the following information: |
· 58.185 (a) A final report shall be prepared for each nonclinical laboratory study and shall include, but not necessarily be limited to, the following: |
· 要求一致。 |
· 第三十三條 (一)研究的名稱、代號及研究目的; (六)受試物和對照品的名稱、縮寫名、代號、批號、穩(wěn)定性、含量、濃度、純度、組分及其他質(zhì)量特性、受試物和對照品制劑的分析結(jié)果,研究用的溶媒、乳化劑及其他介質(zhì)的名稱、批號、有關(guān)的理化性質(zhì)或者生物特性; |
· Section II 9.2 1. Identification of the Study, the Test Item and Reference Item a. A descriptive title; b. Identification of the test item by code or name (IUPAC, CAS number, biological parameters, etc.); c. Identification of the reference item by name; d. Characterisation of the test item including purity, stability and homogeneity. |
· 58.185 (a) 2. Objectives and procedures stated in the approved protocol, including any changes in the original protocol. 4. The test and control articles identified by name, chemical abstracts number or code number, strength, purity, and composition or other appropriate characteristics. 5. Stability of the test and control articles under the conditions of administration. |
· CFDA要求匯報(bào)研究的名稱、代號;OECD要求匯報(bào)研究標(biāo)題;FDA無相關(guān)描述。 · CFDA與FDA要求匯報(bào)研究目的;OECD中無相關(guān)描述。FDA中描述了應(yīng)匯報(bào)方案中聲明的研究目的及程序,及其變更。 · 作為研究的對象-受試品,及對照品,均要求有詳盡的描述及表征。 |
· 第三十三條 (二)所有參與研究的研究機(jī)構(gòu)和委托方的名稱、地址和聯(lián)系方式; (五)專題負(fù)責(zé)人、主要研究者以及參加工作的主要人員姓名和承擔(dān)的工作內(nèi)容; |
· Section II 9.2 2. Information Concerning the Sponsor and the Test Facility a. Name and address of the sponsor; b. Name and address of any test facilities and test sites involved; c. Name and address of the Study Director; d. Name and address of the Principal Investigator(s) and the phase(s) of the study delegated, if applicable; e. Name and address of scientists having contributed reports to the final report. |
· 58.185 (a) 1. Name and address of the facility performing the study and the dates on which the study was initiated and completed. 10. The name of the study director, the names of other scientists or professionals, and the names of all supervisory personnel, involved in the study. |
同: · 研究機(jī)構(gòu)名稱與地址、專題負(fù)責(zé)人名稱。 異: · FDA未要求報(bào)告委托方的信息; · CFDA要求報(bào)告研究機(jī)構(gòu)和委托方的聯(lián)系方式; · FDA特別要求報(bào)告參與到研究中所有管理人員的名字。 |
· 第三十三條 (四)研究起止日期; |
· Section II 9.2 3. Dates Experimental starting and completion dates. |
· 58.185 (a) 1. the dates on which the study was initiated and completed. |
· CFDA與FDA要求報(bào)告研究的起止日期,而OECD要求報(bào)告試驗(yàn)的開始結(jié)束日期。 |
· 第三十三條 (三)研究所依據(jù)的試驗(yàn)標(biāo)準(zhǔn)、技術(shù)指南或者文獻(xiàn)以及研究遵守的非臨床研究質(zhì)量管理規(guī)范; |
- |
- |
· 第三十三條 (十)各種指標(biāo)的檢測方法和頻率; |
· Section II 9.2 5. Description of Materials and Test Methods a. Description of methods and materials used; b. Reference to OECD Test Guideline or other test guideline or method. |
· 58.185 (a) 6. A description of the methods used. 同: · 均要求匯報(bào)檢測方法。 異: · CFDA要求匯報(bào)檢測的頻率; · OECD要求描述使用的材料。 |
_ |
· 第三十三條 (七)實(shí)驗(yàn)系統(tǒng)的種、系、數(shù)量、年齡、性別、體重范圍、來源、實(shí)驗(yàn)動(dòng)物合格證號、接收日期和飼養(yǎng)條件; (八)受試物和對照品的給藥途徑、劑量、方法、頻率和給藥期限; (九)受試物和對照品的劑量設(shè)計(jì)依據(jù); |
- |
· 58.185 (a) 7. A description of the test system used. Where applicable, the final report shall include the number of animals used, sex, body weight range, source of supply, species, strain and substrain, age, and procedure used for identification. 8. A description of the dosage, dosage regimen, route of administration, and duration. |
_ |
· 第三十三條 (十一)分析數(shù)據(jù)所采用的統(tǒng)計(jì)方法; |
- |
· 58.185 (a) 3. Statistical methods employed for analyzing the data. |
· CFDA與FDA要求一致,OECD無相關(guān)要求。 |
· 第三十三條 (十二)結(jié)果和結(jié)論; |
· Section II 9.2 6. Results a. A summary of results; b. All information and data required by the study plan; d. An evaluation and discussion of the results and, where appropriate, conclusions. c. A presentation of the results, including calculations and determinations of statistical significance; |
· 58.185 (a) 11. A description of the transformations, calculations, or operations performed on the data, a summary and analysis of the data, and a statement of the conclusions drawn from the analysis. |
· 要求一致 |
· 第三十三條 (十三)檔案的保存地點(diǎn); |
· Section II 9.2 7. Storage The location(s) where the study plan, samples of test and reference items, specimens, raw data and the final report are to be stored. |
· 58.185 (a) 13. The locations where all specimens, raw data, and the final report are to be stored. |
· 要求一致 |
· 第三十三條 (十四)所有影響本規(guī)范符合性、研究數(shù)據(jù)的可靠性的情況; (十六)專題負(fù)責(zé)人簽署的、陳述研究符合本規(guī)范的聲明; |
· Section II 9.2 9. A description of all circumstances that may have affected the quality or integrity of the data. |
· 58.185 (a) 9.1.3. The extent of compliance with these Principles of Good Laboratory Practice should be indicated. |
· CFDA與FDA要求匯報(bào)影響數(shù)據(jù)質(zhì)量、合規(guī)性的問題,而OECD要求匯報(bào)GLP準(zhǔn)則的符合程度。雖然表述不同,但要求其實(shí)是一致的。 · CFDA要求SD簽署陳述符合GLP的聲明,OECD和FDA中無相關(guān)描述。 |
· 第三十三條 (十五)質(zhì)量保證部門簽署的質(zhì)量保證聲明; |
· Section II 9.2 4. Statement A Quality Assurance Programme statement listing the types of inspections made and their dates, including the phase(s) inspected, and the dates any inspection results were reported to management and to the Study Director and Principal Investigator(s), if applicable. This statement would also serve to confirm that the final report reflects the raw data. |
· 58.185 (a) 14. The statement prepared and signed by the quality assurance unit as described in Sec. 58.35(b)(7). 58.35 (b) (7) Prepare and sign a statement to be included with the final study report which shall specify the dates inspections were made and findings reported to management and to the study director. |
· 要求一致 |
· 第三十三條 (十七)多場所研究的情況下,還應(yīng)當(dāng)包括主要研究者簽署姓名、日期的相關(guān)試驗(yàn)部分的報(bào)告。 |
· Section II 9.2 9.1.2. Reports of Principal Investigators or scientists involved in the study should be signed and dated by them. |
· 58.185 (a) 12. The signed and dated reports of each of the individual scientists or other professionals involved in the study. |
· 要求一致 |
· 第三十四條 總結(jié)報(bào)告被批準(zhǔn)后,需要修改或者補(bǔ)充時(shí),應(yīng)當(dāng)以修訂文件的形式予以修改或者補(bǔ)充,詳細(xì)說明修改或者補(bǔ)充的內(nèi)容、理由,并經(jīng)質(zhì)量保證部門審查,由專題負(fù)責(zé)人簽署姓名和日期予以批準(zhǔn)。為了滿足注冊申報(bào)要求修改總結(jié)報(bào)告格式的情況不屬于總結(jié)報(bào)告的修訂。 |
· Section II 9.1.4. Corrections and additions to a final report should be in the form of amendments. Amendments should clearly specify the reason for the corrections or additions and should be signed and dated by the Study Director. 9.1.5. Reformatting of the final report to comply with the submission requirements of a national registration or regulatory authority does not constitute a correction, addition or amendment to the final report. |
· 58.185 (c) Corrections or additions to a final report shall be in the form of an amendment by the study director. The amendment shall clearly identify that part of the final report that is being added to or corrected and the reasons for the correction or addition, and shall be signed and dated by the person responsible. |
· 對于報(bào)告的修訂,要求一致。 · CFDA提出要求報(bào)告修訂案經(jīng)過質(zhì)量保證部審查。 · CFDA與OECD中明確指出為了滿足注冊申報(bào)要求修改總結(jié)報(bào)告格式的情況不屬于總結(jié)報(bào)告的修訂。 歡迎各位同行進(jìn)行勘誤及指出不足之處。 |
參考文獻(xiàn):
[1] US FDA Good Laboratory Practice Regulations 21 CFR 58,effective June 20, 1979 and subsequent amendments
[2] OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted November 26th, 1997 by decision of the OECD Council [C (97)186/Final]
[3] 國家食品藥品監(jiān)督管理總局,藥物非臨床研究質(zhì)量管理規(guī)范,2017年9月1日生效